Chemoimmunotherapy before surgery for triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a combination of chemotherapy and immunotherapy given before surgery for triple-negative breast cancer. It aims to shrink the tumor and improve outcomes. The treatment is given intravenously.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with triple-negative breast cancer (stage T1c-T3, N0-N2).
- You have not had surgery or any other treatment for this breast cancer yet.
- Your overall health is good (able to do daily activities and look after yourself).
- You are willing to provide a sample of your tumor tissue (either a block or slides) for testing.
- If you can become pregnant, you agree to use effective birth control during and after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
This trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin + paclitaxel) before surgery can improve outcomes for people with early-stage triple-negative breast cancer. It aims to shrink the tumor and increase the chance of a complete response.
This trial tests a combination of an immunotherapy drug (pembrolizumab) plus two chemotherapy drugs (carboplatin and paclitaxel) given before surgery for people with early-stage, triple-negative breast cancer. The goal is to see if this treatment helps shrink or eliminate the tumor before it's removed.
This trial tests a combination of stereotactic body radiation therapy (SBRT), chemotherapy, and an immunotherapy drug called AK104 given before surgery to treat triple-negative breast cancer. It aims to see if this approach can shrink tumors more effectively and help patients avoid a mastectomy.
This trial tests if adding the immunotherapy drug camrelizumab to standard chemotherapy before surgery can improve outcomes for women with early or locally advanced triple-negative breast cancer. It is for those who haven't had treatment yet and are candidates for surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.